News

AstraZeneca fails endpoint
Enlarge image

BusinessUKSweden

AstraZeneca fails endpoint

08.04.2013 - AstraZeneca's arthritis pill fostamatinib is proven inferior to competitor drugs in a late-stage clinical trial.

While the first-in-class oral rheumatoid (RA) arthritis drug proved to be efficient as measured by ACR20 reponse it failed to halt the progression of joint damage as compared with placebo in the OSKIRA-1 Phase III study. In December, fastamatinib was shown to be inferior in efficacy compared to Abbvie’s injectible RA blockbuster antibody Humira (adalimumab),reducing its ability to compete in the US$20bn-plus RA market. AstraZeneca’ RA pill also increased blood pressure and led to diarrhea.

"Our misgiving is that fostamatinib appears to be inferior to Humira on efficacy and now the adverse events seem to pitch it below Pfizer's Xeljanz, (– another RA pill in late-stage development –) so it is hard to see where the product will fit," said Panmure Gordon analyst Savvas Neophytou.

AstraZeneca, which currently announced the restructuring of its R&D, licensed fostamatinib in 2010 from Rigel Pharmaceuticals. However, after the current study results, analysts forecasted only low fostamatinib sales, averaging just US$171m in 2016. Humira, by contrast, has annual worldwide sales of more than $9 billion but has become under pressure by new RA drugs such as Roche’s RoActemra.

With last year's loss of exclusivity on schizophrenia drug Seroquel, and Nexium for stomach acid and cholesterol fighter Crestor set for U.S. patent expiries in 2014 and 2016, AstraZeneca faces one of the industry's steepest "cliffs" of patent expiries.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/astrazeneca-fails-endpoint.html

RegulationEU

21.01.2015 The EMA is asking for comments on how to implement the transparency rules of EU Clinical Trial Regulation, pointing to the new clinical trial portal and database as the main instrument.

Stock marketsEUGermany

21.01.2015 2014 was a record year for biotech companies on the European stock market, with a total of €2.4bn raised in the year - 25% more than in the year before.

ResearchEUUK

20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck. 

Stock ExchangeUKDenmarkFrance

16.01.2015 It's time to get used to weekly IPO plans by European biotechs. UK's drug discovery firm Redx Pharma Ltd, established just five years ago, has come of age with their £80m (€105m) IPO plans.

M&ASwitzerland

14.01.2015 Pharma kingpin Roche has launched a billion-dollar transaction for a total of US$1.2bn (€1bn), taking over the majority of US cancer specialist Foundation Medicine.

PoliticsEU

14.01.2015 The European Parliament has backed the legislation allowing individual countries to restrict or prohibit the cultivation of genetically modified crops that have been authorised at EU level.

M&AIrelandUK

13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.

M&ASwitzerlandFrance

09.01.2015 The excitement surrounding CRISPR genome editing shows no sign of abating. This month, Novartis and US biotech Intellia Therapeutics became the first ever biotech-pharma collaboration to use the groundbreaking technology.

PoliticsBelgium

08.01.2015 Belgian cell therapy specialist Cardio3 Biosciences joins the immuno-oncology arena with the acquisition of Celdara Medical's cancer division Oncyte for US$180m.

PoliticsIrelandEU

06.01.2015 With the aim to utilise Ireland’s many natural resources and keep abreast of the latest EU developments in bioeconomy, a multi-disciplinary team has been funded to maximise national income, exports and job creation related to Ireland’s bioeconomy.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS0.39 CHF21.87%
  • THERAMETRICS0.07 CHF16.67%
  • SANTHERA97.50 CHF5.98%

FLOP

  • 4SC0.78 EUR-8.24%
  • ADDEX3.36 CHF-5.62%
  • BIOFRONTERA1.95 EUR-2.50%

TOP

  • CYTOS0.39 CHF77.3%
  • ADDEX3.36 CHF44.2%
  • BB BIOTECH253.50 EUR28.1%

FLOP

  • ACTELION99.25 CHF-16.3%
  • BIOFRONTERA1.95 EUR-15.2%
  • 4SC0.78 EUR-13.3%

TOP

  • SANTHERA97.50 CHF2355.9%
  • BB BIOTECH253.50 EUR100.5%
  • FORMYCON12.40 EUR61.0%

FLOP

  • CYTOS0.39 CHF-88.2%
  • 4SC0.78 EUR-53.3%
  • MOLOGEN5.79 EUR-50.2%

No liability assumed, Date: 27.01.2015